O3K consortium to study paediatric anticancers
This article was originally published in Scrip
Executive Summary
Oral Off-patent Oncology drugs for Kids (O3K), a European consortium that aims to develop paediatric formulations of existing anticancers, expects to begin its first clinical trials in November.